Conclusionintervention. Thus, RU <strong>486</strong>/PG may be unwarranted in asignificant number of women. Calculated at the 30 per centlevel, this could amoun t to 18,000 of the 60,000 Frenchwomen so treated! Can we be disturbed about chemicallyfed plants <strong>and</strong> animals <strong>and</strong> remain unconcerned aboutchemically fed women?There is a dearth of research, development, <strong>and</strong>implementation of birth control, abortion, <strong>and</strong> reproductivetechnology as the promoters of RU <strong>486</strong> claim. What is moreimportant, however, is that there is a dearth of appropriatetechnology for women. And most of the technology that hasbeen developed requires medical supervision <strong>and</strong> control.There has been a virtual non-existence of research intocondom improvement, barrier methods, <strong>and</strong> menstrualextraction, in contrast to the enthusiasm for the pill, IUDs,injectables, <strong>and</strong> sterilization. Most of the reproductivetechnology <strong>and</strong> drugs thus far, as well as those now beingproposed, are attended by risk, harm <strong>and</strong>, in some cases,death to women.People expect <strong>and</strong> accept technological solutions asunmitigated progress. The history of the medicalization ofreproduction in the west has spawned the biomedical controlof women’s reproductive lives, the technological <strong>and</strong> surgicalmanagement of pregnancy <strong>and</strong> childbirth, <strong>and</strong> thedevelopment <strong>and</strong> continued use of questionable drugs <strong>and</strong>technologies. RU <strong>486</strong>/PG cannot be seen apart from thishistory of technological fixes <strong>and</strong> medical control of women’slives.For example, why are the abortion options in most westerncountries completely medicalized? We see this again withRU <strong>486</strong>, although the rhetoric of demedicalization isemphasized. Without exception, however, every physiciannow working with the drug emphasizes that strict medicalsupervision is necessary. Strict medical supervision is alsostrict medical control. When the American MedicalAssociation voted to support the testing of the drug in the115
RU <strong>486</strong>United States, it stated: ‘This is not an abortion issue; this isan issue of scientific research for a drug that can be useful formany different medical problems’ (Lee, 1990:2). TheAssociation feared that women’s health activists would importthe drug, <strong>and</strong> delegates supporting the resolution lamentedthat the drug would be used without proper medicalsupervision. The other side of this fear is that RU <strong>486</strong>/PGwould be launched outside the parameters of medical control.The push for medical control of abortion is in keepingwith the historical position of doctors in the west toward allforms of reproductive technologies, including birthing <strong>and</strong>birth control, as well as abortion methods. Historically, itwas the medical lobby that influenced law <strong>and</strong> public policy,keeping birth control <strong>and</strong> abortion under the control ofphysicians. Robert Dickinson, a leading advocate forgynecologists in the early 20th century, who promotedcontraception with Margaret Sanger, urged his physiciancolleagues to keep birth control in their own h<strong>and</strong>s <strong>and</strong> notlet it go to the radicals (Gordon, 1976:249–300). The radicals,of course, were mostly women who were dem<strong>and</strong>ing birthcontrol along with political <strong>and</strong> legal change. Many of thesewomen succumbed to the pressure promoting physiciancontrol <strong>and</strong> the strict medicalization of birth control.Ultimately, when birth control was approved in the UnitedStates, legislation m<strong>and</strong>ated that only doctors could import,mail, <strong>and</strong> dispense it.Reproductive technological history seems to be repeatingitself. The current feminist campaigns for abortion <strong>and</strong> forRU <strong>486</strong>/PG seem confined in this same straitjacket ofadvocating for abortion choices for women, but within theboundaries established by the medical profession <strong>and</strong>population planners. Population organizations, such as thePopulation Crisis Committee <strong>and</strong> the Population Council,the developer of Norplant, have sponsored research on RU<strong>486</strong>/PG <strong>and</strong> are promoting its distribution.Of concern is the current promotional collaboration116
- Page 2 and 3:
Renate Klein is Lecturer in Women
- Page 4 and 5:
RU 486Misconceptions,Myths and Mora
- Page 6 and 7:
ACKNOWLEDGEMENTSWe would like to ex
- Page 8 and 9:
CONTENTSINTRODUCTION 1CHAPTER ONETh
- Page 10 and 11:
INTRODUCTIONInitial euphoria greete
- Page 12 and 13:
IntroductionUnfortunately, objectio
- Page 14 and 15:
Introductiondo not know or do not a
- Page 16 and 17:
Introductionused widely for years a
- Page 18 and 19:
CHAPTER ONEThe History of RU 486RU
- Page 20 and 21:
The History of RU 486consultants ar
- Page 22 and 23:
The History of RU 486Events in Fran
- Page 24 and 25:
The History of RU 486service of wom
- Page 26 and 27:
The History of RU 486The result app
- Page 28 and 29:
The History of RU 486developing cou
- Page 30 and 31:
The History of RU 486University Hos
- Page 32 and 33:
The History of RU 486pharmacovigila
- Page 34 and 35:
CHAPTER TWOClaims for RU 486/PG Abo
- Page 36 and 37:
Claims for RU 486/PG Abortionsevera
- Page 38 and 39:
Claims for RU 486/PG Abortionthe Br
- Page 40 and 41:
Claims for RU 486/PG Abortionan imm
- Page 42 and 43:
Claims for RU 486/PG Abortionby the
- Page 44 and 45:
Claims for RU 486/PG Abortionby the
- Page 46 and 47:
Claims for RU 486/PG Abortionfrom A
- Page 48 and 49:
Claims for RU 486/PG Abortioncommen
- Page 50 and 51:
Claims for RU 486/PG AbortionSome s
- Page 52 and 53:
Claims for RU 486/PG Abortionbreeze
- Page 54 and 55:
Claims for RU 486/PG Abortion18 per
- Page 56 and 57:
Claims for RU 486/PG Abortion1. RU
- Page 58 and 59:
Claims for RU 486/PG AbortionRU 486
- Page 60 and 61:
Claims for RU 486/PG Abortionwider
- Page 62 and 63:
Claims for RU 486/PG Abortionmedica
- Page 64 and 65:
Claims for RU 486/PG Abortionreligi
- Page 66 and 67:
What Is RU 486 and How Does It Work
- Page 68 and 69:
What Is RU 486 and How Does It Work
- Page 70 and 71:
What Is RU 486 and How Does It Work
- Page 72 and 73:
What Is RU 486 and How Does It Work
- Page 74 and 75: What Is RU 486 and How Does It Work
- Page 76 and 77: What Is RU 486 and How Does It Work
- Page 78 and 79: What Is RU 486 and How Does It Work
- Page 80 and 81: What Is RU 486 and How Does It Work
- Page 82 and 83: What Is RU 486 and How Does It Work
- Page 84 and 85: What Is RU 486 and How Does It Work
- Page 86 and 87: What Is RU 486 and How Does It Work
- Page 88 and 89: What Is RU 486 and How Does It Work
- Page 90 and 91: The Role of Prostaglandins: Known a
- Page 92 and 93: The Role of Prostaglandins: Known a
- Page 94 and 95: The Role of Prostaglandins: Known a
- Page 96 and 97: The Role of Prostaglandins: Known a
- Page 98 and 99: The Role of Prostaglandins: Known a
- Page 100 and 101: The Role of Prostaglandins: Known a
- Page 102 and 103: The Role of Prostaglandins: Known a
- Page 104 and 105: The Role of Prostaglandins: Known a
- Page 106 and 107: The Role of Prostaglandins: Known a
- Page 108 and 109: The Role of Prostaglandins: Known a
- Page 110 and 111: The Role of Prostaglandins: Known a
- Page 112 and 113: The Role of Prostaglandins: Known a
- Page 114 and 115: The Role of Prostaglandins: Known a
- Page 116 and 117: The Role of Prostaglandins: Known a
- Page 118 and 119: The Role of Prostaglandins: Known a
- Page 120 and 121: The Role of Prostaglandins: Known a
- Page 122 and 123: ConclusionInstead, Baulieu uses the
- Page 126 and 127: Conclusionbetween population contro
- Page 128 and 129: ConclusionThis article, appearing i
- Page 130 and 131: Conclusion‘a whole net of relatio
- Page 132 and 133: ENDNOTESChapter One1The paten t lic
- Page 134 and 135: Endnotes12The Journal Officiel publ
- Page 136 and 137: Endnotesin Gynecology and Obstetric
- Page 138 and 139: Endnotesof menses. On the third day
- Page 140 and 141: EndnotesAnother such example is the
- Page 142 and 143: Bibliographyand Segal, Sheldon (Eds
- Page 144 and 145: Bibliographyprostaglandin F 2•. A
- Page 146 and 147: BibliographyDelaney, Anne. (1991, 2
- Page 148 and 149: Bibliographyresponses to the steroi
- Page 150 and 151: Bibliographyabnormalities resulting
- Page 152 and 153: Bibliographyprogesterone receptor b
- Page 154 and 155: BibliographyOdlind, Viveca and Birg
- Page 156 and 157: BibliographyBinding of the anti-pro
- Page 158 and 159: BibliographyUlmann, André, Teutsch
- Page 160: Bibliographytermination by vacuum a